Safety Reporting
Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.
The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
Clinical Research News
Kommende kliniske studier
-
University of TennesseeWoodcock Institute for the Advancement of Neurocognitive Research and...Har ikke rekruttert ennåMotor ferdigheter | Sunn | Utøvende funksjon
-
University of Texas Southwestern Medical CenterMerck Sharp & Dohme LLCHar ikke rekruttert ennåAnal plateepitelkarsinom
-
Universita di VeronaAzienda Ospedaliera Universitaria Integrata VeronaHar ikke rekruttert ennåLeddgikt | Degenerativ leddsykdom i kneItalia
-
University of Wisconsin, MadisonAlkermes, Inc.Har ikke rekruttert ennå
-
Virginia Commonwealth UniversityHar ikke rekruttert ennåCerebralt ødem | StrålingsnekroseForente stater
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH); Icahn School of Medicine at...Har ikke rekruttert ennåKetamin | fMRI | Depresjon - alvorlig depressiv lidelse | rTMS | Behandlingsresistent depresjon (TRD)Forente stater
-
Weill Medical College of Cornell UniversityBD2 LLCHar ikke rekruttert ennåfMRI | Bipolar lidelse (BD) | rTMS | Bipolar 1 depresjonForente stater
-
Xentria, Inc.Har ikke rekruttert ennå
-
Yale UniversityNational Institute of Mental Health (NIMH)Har ikke rekruttert ennå
-
Cambridge University Hospitals NHS Foundation TrustUniversity of CambridgeRekrutteringFeokromocytom | Feokromocytom/Paragangliom | Feokromocytom, metastatisk | Feokromocytom ondartet | Pheokromocytom og paraganglioma (PPGL)Storbritannia
-
Carl Zeiss Meditec-Dublin CoCeRekrutteringEpiretinal membran | Retina sykdom | Tørr aldersrelatert makuladegenerasjon | Vitreoretinal abnormitet | Macular Abnormalities | Intraretinal Hyporeflective Space | Subretinal Hyporeflective Space | IS/OS (Ellipsoid Zone) Disruption | Retinal Pigment Epithelium (RPE) Elevation | Retinal Pigment Epithelium...Forente stater
-
Celest Therapeutics (Shanghai) Co., Ltd.The First Affiliated Hospital of Anhui Medical UniversityRekruttering
Clinical Research Jobs
-
Czechia - Brno
-
Belgium - Leuven
-
United Kingdom - Tranent
-
Romania - Bucharest
-
United StatesCanada - Québec - Quebec
-
United Kingdom - Guildford
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China